The Lancet Respiratory Medicine
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Breaking barriers: holistic assessment of ability to work in patients with sarcoidosis..
12:848-851.
2024
-
Protecting respiratory health of athletes: an Olympic challenge.
12:509-510.
2024
-
Early mobilisation in the intensive care unit: shifting from navigating risks to a patient-centred approach.
12:341-343.
2024
-
ACT trials: long-term outcomes.
11:e50-e50.
2023
-
Effects of remdesivir in patients hospitalised with COVID-19 a systematic review and individual patient data meta- analysis of randomised controlled trials.
11:453-464.
2023
-
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials.
11:453-464.
2023
-
Weaning from mechanical ventilation in intensive care units across 50 countries (WEAN SAFE): a multicentre, prospective, observational cohort study.
11:465-476.
2023
-
Prognostic factors associated with mortality among patients receiving venovenous extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis.
11:235-244.
2023
-
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.
11:87-96.
2023
-
Chronic cough and cough hypersensitivity: from mechanistic insights to novel antitussives.
10:1113-1115.
2022
-
Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial.
10:1160-1168.
2022
-
Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial.
10:1169-1177.
2022
-
Smoking and e-cigarette use: key variables in testing IgA-oriented intranasal vaccines.
10:822-824.
2022
-
A sudden deterioration in idiopathic pulmonary fibrosis.
9:1342-1342.
2021
-
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial.
9:1141-1153.
2021
-
Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019.
9:1030-1049.
2021
-
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.
9:763-772.
2021
-
Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context.
9:655-664.
2021
-
Neutrophilic asthma: misconception or misnomer?.
9:441-443.
2021
-
Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial.
9:498-510.
2021
-
Effect of a single day of increased as-needed budesonide–formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study.
9:149-158.
2021
-
Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000–18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database.
9:33-42.
2021
-
Decreasing antibiotic use, the gut microbiota, and asthma incidence in children: evidence from population-based and prospective cohort studies.
8:1094-1105.
2020
-
Use of facemasks during the COVID-19 pandemic.
8:954-955.
2020
-
Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017.
8:585-596.
2020
-
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
8:453-460.
2020
-
Asthma: moving toward a global children's charter.
7:299-300.
2019
-
Time to focus on paediatric critical care survivorship.
7:103-105.
2019
-
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial.
7:46-59.
2019
-
Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017.
7:69-89.
2019
-
Beyond the guidelines for non-invasive ventilation in acute respiratory failure: implications for practice.
6:935-947.
2018
-
Idiopathic pulmonary fibrosis: idiopathic no more?.
6:84-85.
2018
-
Palliative care in interstitial lung disease: living well.
5:968-980.
2017
-
Personalised medicine for IPF: getting closer, but not there yet.
5:836-837.
2017
-
Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?.
5:591-598.
2017
-
Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial.
4:797-806.
2016
-
Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution – Authors' reply.
4:e48-e48.
2016
-
Early life nasal microbiota in infants with cystic fibrosis.
4:595-596.
2016
-
Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis.
4:381-389.
2016
-
Blood or sputum eosinophils to guide asthma therapy?.
3:824-825.
2015
-
Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
3:692-701.
2015
-
Respiratory risks from household air pollution in low and middle income countries.
2:823-860.
2014
-
Global differences in lung function by region (PURE): an international, community-based prospective study.
1:599-609.
2013
-
Polygenic risk and the development and course of asthma: an analysis of data from a four-decade longitudinal study.
1:453-461.
2013
-
Are inhaled longacting β2 agonists detrimental to asthma?.
1:339-346.
2013
-
Asthma: management of severe disease.
1:e3-e4.
2013
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)